SS Innovations International, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SS Innovations International, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.48M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $20.65M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $5.88M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $1.44M | Dec 20, 2024 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $5.88M | Dec 20, 2024 |
| FY2023 | Dec 31, 2022 | $1.44M | Dec 20, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.54M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $8.45M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $725.5K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $60.6K | Dec 20, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.13M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($19.15M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($20.88M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($3.21M) | Dec 20, 2024 |
| FY2022 | Dec 31, 2021 | ($1.48M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($1.12M) | Nov 4, 2022 |
| FY2020 | Dec 31, 2019 | ($3.39M) | Sep 6, 2022 |
| FY2019 | Dec 31, 2018 | ($960.3K) | Feb 22, 2022 |
| FY2018 | Dec 31, 2017 | ($1.04M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($485.0K) | Mar 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.19M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($18.98M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($20.27M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($2.96M) | Dec 20, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.69M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $2.49M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $1.06M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $987.4K | Dec 20, 2024 |
| FY2022 | Dec 31, 2021 | $1.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.0K | Nov 4, 2022 |
| FY2020 | Dec 31, 2019 | $60.9K | Sep 6, 2022 |
| FY2019 | Dec 31, 2018 | $27.1K | Feb 22, 2022 |
| FY2018 | Dec 31, 2017 | $71.2K | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $127.6K | Mar 29, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.85M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $10.16M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $10.06M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $1.94M | Dec 20, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.54M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($9.50M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($15.36M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($5.99M) | Dec 20, 2024 |
| FY2022 | Dec 31, 2021 | ($363.0K) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($90.5K) | Nov 4, 2022 |
| FY2020 | Dec 31, 2019 | ($424.1K) | Sep 6, 2022 |
| FY2019 | Dec 31, 2018 | ($443.3K) | Feb 22, 2022 |
| FY2018 | Dec 31, 2017 | ($446.9K) | Apr 16, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.66M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $661.5K | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $453.3K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $220.3K | Mar 22, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.23M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $42.39M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $31.52M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $6.98M | Dec 20, 2024 |
| FY2022 | Dec 31, 2021 | $428.6K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $317.9K | Nov 4, 2022 |
| FY2020 | Dec 31, 2019 | $132.5K | Sep 6, 2022 |
| FY2019 | Dec 31, 2018 | $145.4K | Feb 22, 2022 |
| FY2018 | Dec 31, 2017 | $510.0K | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $292.2K | Mar 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.01M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $28.93M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $11.80M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $9.66M | Dec 20, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.22M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $13.46M | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | $19.72M | Mar 10, 2026 |
| FY2024 | Dec 31, 2022 | ($2.68M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2021 | $585.6K | Dec 20, 2024 |
| FY2022 | Dec 31, 2020 | ($869.0K) | Mar 31, 2023 |
| FY2020 | Dec 31, 2019 | ($1.06M) | Sep 6, 2022 |
| FY2020 | Dec 31, 2018 | ($223.0K) | Sep 6, 2022 |
| FY2019 | Dec 31, 2017 | $101.1K | Feb 22, 2022 |
| FY2018 | Dec 31, 2016 | ($355.1K) | Apr 16, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($55.79M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($43.66M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($24.51M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($3.63M) | Dec 20, 2024 |
| FY2022 | Dec 31, 2021 | ($8.48M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($6.99M) | Nov 4, 2022 |
| FY2020 | Dec 31, 2019 | ($5.87M) | Sep 6, 2022 |
| FY2019 | Dec 31, 2018 | ($2.48M) | Feb 22, 2022 |
| FY2018 | Dec 31, 2017 | ($1.52M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($485.0K) | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.21M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $466.5K | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $2.02M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $217.2K | Dec 20, 2024 |
| FY2021 | Dec 31, 2021 | $405.8K | Nov 4, 2022 |
| FY2021 | Dec 31, 2020 | $160.7K | Nov 4, 2022 |
| FY2019 | Dec 31, 2019 | $28.5K | Feb 22, 2022 |
| FY2019 | Dec 31, 2018 | $35.7K | Feb 22, 2022 |
| FY2019 | Dec 31, 2017 | $452.6K | Feb 22, 2022 |
| FY2018 | Dec 31, 2016 | $248.2K | Apr 16, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $510.2K | Dec 20, 2024 |
| FY2023 | Dec 31, 2022 | $589.9K | Dec 20, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Dec 20, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Nov 4, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Sep 6, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Dec 20, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Nov 4, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Sep 6, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 194.17M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 171.58M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 170.71M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 128.16M | Dec 20, 2024 |
| FY2022 | Dec 31, 2021 | 37.85M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 25.72M | Nov 4, 2022 |
| FY2020 | Dec 31, 2019 | 21.86M | Sep 6, 2022 |
| FY2019 | Dec 31, 2018 | 21.01M | Feb 22, 2022 |
| FY2018 | Dec 31, 2017 | 20.64M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | 19.00M | Mar 29, 2018 |